Active substance
Factor viii inhibitor bypassing fraction
- SFDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FEIBA 25 U/ml POWDER & SOLVENT | 25 U/ml | Powder and solvent for solution for infusion · Parenteral use | 1 Bottle | SAR 1645.30 | Biological · Prescription | Takeda Manufacturing AG | Valid |
| FEIBA 50U POWDER&SOLVENT | 50 U/ml | Powder and solvent for solution for infusion · Intravenous use | 1 Bottle | SAR 1645.30 | Biological · Prescription | Takeda Manufacturing AG | Valid |
| FEIBA 50U POWDER&SOLVENT | 50 U/ml | Powder and solvent for solution for infusion · Intravenous use | 1 Vial | SAR 8226.45 | Biological · Prescription | BAXTER AG - AUSTRIA | Withdrawn by MAH · Not Marketed |
| FEIBA 50U/ml POWDER&SOLVENT | 50 U/ml | Powder and solvent for solution for infusion · Parenteral use | 1 Bottle | SAR 3246.25 | Biological · Prescription | BAXTER AG - AUSTRIA | Withdrawn by MAH · Not Marketed |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.